.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A single-center, triple-blind, randomized, placebo-controlled pilot trial evaluated the effect of citicoline on cognitive and functional recovery in 60 adults with mild-to-moderate traumatic brain injury. Patients received citicoline 1000 mg/day or placebo for 90 days. At day 90, patients receiving citicoline demonstrated significantly better cognitive and functional outcomes. Mean MMSE scores were 25.2 versus 21.5 with placebo, while Barthel Index scores were 85.0 versus 70.0 and GOS-E scores were 5.2 versus 3.6; all comparisons had P<0.001. New or worsening intracerebral hemorrhage occurred in 2 patients receiving citicoline and 3 receiving placebo, with no significant difference between groups. The findings suggest that citicoline may improve cognitive and functional recovery following mild-to-moderate TBI, although the authors emphasize that larger multicenter trials are required to confirm these preliminary findings.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A single-center, triple-blind, randomized, placebo-controlled pilot trial evaluated the effect of citicoline on cognitive and functional recovery in 60 adults with mild-to-moderate traumatic brain injury. Patients received citicoline 1000 mg/day or placebo for 90 days. At day 90, patients receiving citicoline demonstrated significantly better cognitive and functional outcomes. Mean MMSE scores were 25.2 versus 21.5 with placebo, while Barthel Index scores were 85.0 versus 70.0 and GOS-E scores were 5.2 versus 3.6; all comparisons had P<0.001. New or worsening intracerebral hemorrhage occurred in 2 patients receiving citicoline and 3 receiving placebo, with no significant difference between groups. The findings suggest that citicoline may improve cognitive and functional recovery following mild-to-moderate TBI, although the authors emphasize that larger multicenter trials are required to confirm these preliminary findings.
Today
A randomized trial shows oral DL-3-n-butylphthalide (200 mg thrice daily) significantly slows functional decline in spinocerebellar ataxia type 3 over 12 months, improving SARA and SCAFI scores with favorable safety and zero serious adverse events.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
Last week
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
Last week
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
Last week
